8040威尼斯(中国)

Be the most trusted biotech company

2026-06-17

STEAP1×CD3×CD28 Tri-specific TCE HLX3902 Receives China Clinical Approval, Promising Breakthrough in “Cold Tumour” Therapy
2026-06-17

Exploring Earlier-Stage Treatment Potential: Henlius’ Phase 2 Clinical Trial of HLX43 in Combination with Serplulimab for Neoadjuvant Treatment of NSCLC Approved for Clinical Trial in Australia
2026-06-16

Henlius Successfully Completes International Phase 3 Trial of HLX04-O for Ophthalmic Indication
2026-06-09

Henlius’ Serplulimab Approved for Perioperative Gastric Cancer, Pioneering a Chemotherapy-Sparring Adjuvant Approach
2026-06-05

Globalisation 2.0 | Henlius Advances Global Clinical Development of Pembrolizumab Biosimilar with First U.S. Patient Dosed
2026-06-02

Featured in Both The Lancet and ASCO: Henlius’ Serplulimab Pioneers a New Perioperative Chemotherapy-Sparring Regimen for Gastric Cancer
2026-05-31

ASCO 2026 | Henlius Accelerates Global Development of Its PD-L1 ADC, Demonstrating Promising Activity Across Multiple Difficult-to-Treat NSCLC Subgroups and Potential for Earlier-Line Development
2026-05-29

Henlius' Pertuzumab Approved in China, Solidifying Breast Cancer Strategy as the First China-US-EU Approved Chinese Trastuzumab-Pertuzumab Combination
2026-05-28

Henlius Advances Global Development of PD-L1 ADC HLX43 as Phase 2/3 MRCT in Previously Treated Advanced sqNSCLC Completes First Patient Dosed in China